To confirm specificity:
Perform Western blot with protein extracts from wild-type and CRISPR/Cas9-generated PDIL5-4 knockout lines. Absence of bands in knockouts confirms target specificity .
Use immunofluorescence colocalization with ER markers (e.g., calnexin/calreticulin), as PDIL5-4 is expected to localize to the endoplasmic reticulum based on homology to PDIL5-1 .
Validate via epitope mapping using synthetic peptides spanning conserved thioredoxin-like domains (e.g., CGHC active motifs) to identify cross-reactivity risks .
Positive controls: Protein extracts from systems overexpressing PDIL5-4 (e.g., transient agroinfiltration in Nicotiana benthamiana).
Negative controls:
Methodological controls: Include housekeeping proteins (e.g., actin) for normalization and no-primary-antibody blots to rule out nonspecific binding .
Time-course infections: Track PDIL5-4 expression levels post-inoculation (e.g., 0, 24, 48 h) via quantitative Western blotting to correlate with viral titer (e.g., qRT-PCR for viral RNA) .
Co-immunoprecipitation (Co-IP): Identify viral interactors using PDIL5-4 antibody-coupled beads, followed by mass spectrometry. Validate with reciprocal IP using viral coat protein antibodies .
Preabsorb the antibody with recombinant PDIL5-4 protein (1:5 molar ratio, 2 h at 4°C) to block specific binding. Compare staining patterns pre/post absorption.
Apply antigen retrieval methods optimized for ER-resident proteins (e.g., citrate buffer pH 6.0 with 0.05% Tween-20) .